Risk of stroke, gangrene from ergot drug interactions.

Article Details

Citation

Copy to clipboard

Wooltorton E

Risk of stroke, gangrene from ergot drug interactions.

CMAJ. 2003 Apr 15;168(8):1015.

PubMed ID

12695387 [ View in PubMed

]

Abstract

Not Available

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Dihydroergocornine	Cytochrome P450 3A4	Protein	Humans	No	Substrate	Details
Dihydroergocristine	Cytochrome P450 3A4	Protein	Humans	No	Substrate	Details
Dihydroergocryptine	Cytochrome P450 3A4	Protein	Humans	No	Substrate	Details
Ergotamine	Cytochrome P450 3A4	Protein	Humans	Unknown	Substrate Inhibitor	Details

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Almotriptan Cabergoline	Cabergoline may increase the vasoconstricting activities of Almotriptan.
Almotriptan Methylergometrine	Methylergometrine may increase the vasoconstricting activities of Almotriptan.
Almotriptan Lisuride	Lisuride may increase the vasoconstricting activities of Almotriptan.
Almotriptan Nicergoline	Nicergoline may increase the vasoconstricting activities of Almotriptan.
Almotriptan Ergoloid mesylate	Ergoloid mesylate may increase the vasoconstricting activities of Almotriptan.